First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial-MedSci.cn

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Paz-Ares, LG; Ramalingam, SS; Ciuleanu, TE; Lee, JS; Urban, L; Caro, RB; Park, K; Sakai, H; Ohe, Y; Nishio, M; Audigier-Valette, C; Burgers, JA; Pluzanski, A; Sangha, R; Gallardo, C; Takeda, M; Linardou, H; Lupinacci, L; Lee, KH; Caserta, C; Provencio, M; Carcereny, E; Otterson, GA; Schenker, M; Zurawski, B; Alexandru, A; Vergnenegre, A; Raimbourg, J; Feeney, K; Kim, SW; Borghaei, H; O'Byrne, KJ; Hellmann, MD; Memaj, A; Nathan, FE; Bushong, J; Tran, P; Brahmer, JR; Reck, M

Paz-Ares, LG (通讯作者)，Univ Complutense, Hosp Univ 12 Octubre, H12O CNIO Lung Canc Clin Res Unit, Av Cordoba SN, Madrid 28041, Spain.;Paz-Ares, LG (通讯作者)，CiberOnc, Av Cordoba SN, Madrid 28041, Spain.

Abstract

Introduction: In CheckMate 227, nivolumab plus ipilimu-mab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

科室

工具

服务